Business
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel
About this update from Bolt Biotherapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. The conference is being held both virtually and at the Boston Convention and Exhibition Center in Boston, Mass. from Nov. 8-12. “These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. “BDC-3042 has a novel mechanism of action that converts immunosuppressive tumor-associated macrophages into immunostimulatory macrophages, which may be an effective treatment approach across many types of cancer. We look forward to presenting these data to the SITC community and remain dedicated to developing novel treatments for patients with solid tumors.” Details about the presentation follow, and a copy of the poster will be available on the Publications section of the Bolt Biotherapeutics website at the start of the poster session. Poster #1348: \"BDC-3042: A Dectin-2 agonistic antibody for tumor-associated macrophage-directed immunotherapy.”Presenter: Justin A. Kenkel, Ph.D.Details: Friday, Nov. 11, 2022, 9:00 a.m. - 8:30 p.m. EST, Poster Hall Key Findings from the Study Tumor-associated macrophages (TAMs) generally support tumor progression by suppressing anti-tumor immune responses. Dectin-2 is expressed by TAMs and agonism of Dectin-2 on TAMs has been shown to drive potent anti-tumor immunity in preclinical animal models. BDC-3042 is an agonistic, Dectin-2-targeted antibody designed to activate TAMs and mediate anti-tumor efficacy, offering a novel approach for macrophage-directed immunotherapy. BDC-3042 is designed to reprogram immunosuppressive TAMs into immunostimulatory cells that drive anti-tumor immunityBDC-3042 selectively binds to Dectin-2-expressing macrophages and induces an array of pro-inflammatory cytokines, chemokines, and antigen presentation moleculesBDC-3042 exhibits minimal binding to and activation of peripheral l...